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Lipopolysaccharide (LPS) binding protein (LBP) is
an acute-phase protein that initiates an immune
response after recognition of bacterial LPS. Here,
we report the crystal structure of murine LBP at
2.9 A˚ resolution. Several structural differences
were observed between LBP and the related
bactericidal/permeability-increasing protein (BPI),
and the LBP C-terminal domain contained a nega-
tively charged groove and a hydrophobic ‘‘phenyl-
alanine core.’’ A frequent human LBP SNP
(allelic frequency 0.08) affected this region, poten-
tially generating a proteinase cleavage site. The
mutant protein had a reduced binding capacity
for LPS and lipopeptides. SNP carriers displayed
a reduced cytokine response after in vivo LPS
exposure and lower cytokine concentrations in
pneumonia. In a retrospective trial, the LBP SNP
was associated with increased mortality rates
during sepsis and pneumonia. Thus, the struc-
tural integrity of LBP may be crucial for fighting
infections efficiently, and future patient stra-
tification might help to develop better therapeutic
strategies.INTRODUCTION
Recognition of microbial products evokes the innate immune
response, which provides the first line of defense against
invading pathogens (Medzhitov and Janeway, 1997). Lipopoly-
saccharide (LPS) Binding Protein (LBP) is a 50 kDa polypeptide
secreted into the bloodstream as a 58–60 kDa glycosylated pro-
tein, and it is induced mainly in the liver as class I acute phase
protein (Schumann et al., 1996; Tobias et al., 1986). LBP medi-
ates potent innate immune responses by recognizing LPS origi-
nating from different Gram-negative bacteria (Mathison et al.,
1992; Rietschel et al., 1996). It can monomerize LPS multimers,
which enables cellular recognition via CD14 and the toll-like
receptor 4 (TLR4)-MD-2 receptor complex by promoting TLR4-
dimerization followed by rapid signal transduction (Hailman
et al., 1994; Schumann et al., 1990; Tsukamoto et al., 2010).
LBP can also detoxify LPS by transferring it to lipoproteins
to limit inflammation (Lamping et al., 1998; Wurfel et al., 1994;
Zweigner et al., 2001), and this function is particularly important
in the lung (Bingle and Craven, 2004). LPB also binds lipopepti-
des (LP) present in almost all types of bacteria and mycoplasm,
and thus might be viewed as a soluble pattern recognition
molecule (Schro¨der et al., 2004; Schumann, 2011).
LBP belongs to a rapidly evolving protein family, found in many
species, termed palate, lung, and nasal epithelium clone (Plunc)
(Bingle and Craven, 2004). Among this family, Bactericidal/
permeability-increasing protein (BPI) is the closest homolog ofImmunity 39, 647–660, October 17, 2013 ª2013 Elsevier Inc. 647
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Figure 1. The Overall Structure of Murine
LBP Reveals Differences to BPI in the
C Terminus
(A) N-terminal, central, and C-terminal domains
are schematically drawn in blue, light blue, and
green, respectively. Phospholipid molecules are
shown in red. b strands are numbered. The disul-
fide bridge is drawn in yellow. The lower panel
shows the LBP protein rotated by 135.
(B) The N-terminal and central domains of human
BPI andmouse LBP are aligned, and the Ca traces
are shown (see also Figure S1 and Table S1).
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Crystallography and Mutational Analysis of LBPLBP (Tobias et al., 1988;Weiss et al., 1978). BPI canalsobindLPS
and is found mainly in the granules of neutrophils (Canny and
Levy, 2008). The BPI structure shows it is a boomerang-shaped
protein consisting of two structurally similar b barrels (Beamer
et al., 1998). Each barrel is made of an antiparallel b sheet with
two flanking a helices forming apolar pockets. LBP and BPI
have substantial sequence homology but markedly different
properties: Whereas BPI neutralizes LPS and has potent bacteri-
cidal activity, LBPcan transfer LPS to its cell-surface receptor and
enhances cellular inflammatory responses to LPS. Mutagenesis
and biochemical experiments have revealed distinct roles for
the different domains of LBP (Han et al., 1994; Ooi et al., 1987;
Schumannetal., 1997).A truncated formofLBPcanbindLPSeffi-
ciently but does not transfer it to CD14 and instead inhibits LPS-
induced activation of peritoneal macrophages. Therefore, it has
been proposed that the LPS-binding site of LBP is located in its
N-terminal and the CD14 interaction site in the C-terminal half.
However, structural differences between LBP and BPI that might
account for their functional differences have not been identified.
Here we describe the crystal structure of LBP at 2.9 A˚ resolu-
tion. The two linker regions between the central and C-terminal
domains differed substantially from those of BPI, leading to rear-
rangement of the C-terminal domain and generating a large
groove near the C-terminal phospholipid binding pocket. In
addition, a hydrophobic ‘‘phenylalanine core’’ was present only648 Immunity 39, 647–660, October 17, 2013 ª2013 Elsevier Inc.in LBP and not in BPI. We also found
a LBP SNP affecting an amino acid in
close proximity to this phenylalanine
core, which is common in the German
population. By computer-modeling, re-
combinant expression and analyzing
sera from individuals differing in LBP
genotype, we found major functional dif-
ferences of the mutant LBP. Finally, by
investigating several large patient co-
horts, we found that the presence of this
LBP variant might influence the clinical
course of sepsis and pneumonia.
RESULTS
TheOverall Structure of LBPDiffers
Substantially from that of BPI
LBP is a highly extended molecule, 33 A˚
wide and 127 A˚ long (Figure 1A). It canbe divided into three domains, an N-terminal domain (residues
37–214), a central domain (residues 26–36, 215–281 and 451–
481), and a C-terminal domain (residues 282–450). The N-termi-
nal domain has a barrel-shaped structure with a long a-helical
backbone, a helix B flanked by a five-stranded b sheet, sheet
N, and a shorter helix, helix A, at the N terminus. The central
domain consists of a twisted, seven-stranded antiparallel b
sheet. The C-terminal domain is topologically similar to the
N-terminal domain with the exception that in place of the N-ter-
minal a helix there is a partially disordered loop referred to as the
‘‘A’ loop.’’ The b sheets in the N-terminal andC-terminal domains
contain twisted and bulged antiparallel b strands wrapped
around each other to form barrel-like structures. Each of the N-
and C-terminal barrels contains a single hydrophobic pocket
with a bound phospholipid molecule.
Mouse LBP has 48% sequence identity with human BPI, and
there are only four single amino-acid gaps in the aligned
sequences (see Figure S1 available online). As predicted from
the sequence homology, the individual N-terminal, central, and
C-terminal domains of LBP and BPI can be superimposed with
Ca root-mean-square (rms) differences of 1.1, 0.5, and 1.2 A˚,
respectively (Figure S2). However, the complete structures
cannot be aligned satisfactorily because of a large displacement
of the C-terminal domain of LBP relative to its N-terminal and
central domains (Figure 1B). This domain displacement derives
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Figure 2. Identification of the A’ Loop and
the Phenylalanine Core of LBP
(A–D) The structures of human BPI (A) and mouse
LBP (B) are shown. The A’ helix and the A’ loop of
BPI and LBP, respectively, are colored in red, and
the central domains in yellow. Residues interacting
with the A’ helix of BPI and the corresponding
residues in LBP are in blue. Structures of the
central and C-terminal interfaces are shown of BPI
(C) and LBP (D). The A’ helix of BPI and A’ loop of
LBP are colored in red, and the central and
C-terminal domains are shown in yellow and gray,
respectively. Side chains of the residues important
in the domain interaction are drawn in blue.
(E) The B’ helices of LBP and BPI are shown as
pink and blue cylinders, respectively.
(F and G) Structures of the C-terminal domains of
LBP (F) and BPI (G) are compared. The phenylal-
anine core formed by six phenylalanines is shown
in blue and labeled. See also Figure S2.
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Crystallography and Mutational Analysis of LBPfrom a structural transition of the A’ helix as seen in BPI into the A’
loop of LBP and tilting of the B’ helix in the C-terminal domain of
LBP (Figure 2). This displacement of the C-terminal domain gen-
erates a wide, negatively charged groove between the C-termi-
nal and central domains, which is absent in BPI (Figure 3).
The N-terminal and central domains of LBP are structurally
similar to those of BPI. The Ca rms differences are 1.1 and
0.5 A˚, consistent with the average structural difference between
proteins with 48% sequence identity (Figures S1 and S2). There
is experimental evidence that the N-terminal domain is the main
site of interaction with LPS (Lamping et al., 1996), in particular
the positively charged residues at its tip. The tip contains
conserved residues with either positively charged or moderately
hydrophobic side chains, and mutations of residues Arg94,Immunity 39, 647–660,Lys95, and Lys99 in human LBP (which
we propose to rename according to
Swissprot P18428 Arg119, Lys120, and
Lys124) abolish LPS binding (Figure 3B).
Furthermore, a synthetic peptide contain-
ing the N-terminal tip region has LPS-
blocking activity (Lamping et al., 1996).
Identification of an A’ Loop and
Phenylalanine Core within the
C-Terminal Domain of LBP
The most noticeable structural difference
between LBP andBPI is the dramatic shift
of the C-terminal domain of LBP relative
to that of BPI. This structural rearrange-
ment appears to be induced by a rela-
tively small number of amino acid
changes in the A’ loop region (Figures
2A–2D; Figure S3) and the loops preced-
ing the B’ helix (Figure 2E–2G). In BPI, the
A’ helix connects the central and C-termi-
nal domains and closes the barrel-like
structure by joining the b9- and b12-
strands of the central and C-terminal do-mains, respectively (Beamer et al., 1997). In LBP, it is replaced by
a loop, the A’ loop, and several strong interactions with b9 and
b12 are missing. Because of this, the b9 and b12 strands are
separated by approximately 20A˚ and the internal region of the
C-terminal barrel is partially open to solvent (Figure 2B). Of the
17 amino acid residues in the A’ helix of BPI, eight are changed
in LBP (Figure S3). Of these, the Phe293 to Ala conversion ap-
pears the most significant; in BPI, Phe293 forms a hydrophobic
core with residues Val36, Ile236, Tyr238, Phe259, and Leu289 of
the central domain and Phe294, Leu406, and Leu458 of the
C-terminal domain (Figure 2C), and this phenylalanine residue
is changed to alanine or valine in the LBPs of different species
(Figure 2D; Figure S3). The side chains of alanine and valine
are too short to penetrate far into the hydrophobic core regionOctober 17, 2013 ª2013 Elsevier Inc. 649
Figure 3. The Specific A’ Helix of LBP Lead-
ing to a Potentional Functional Groove
Allows for Modeling of Human LBP and
Location of Mutations
(A) The surface charge distribution of LBP is shown
according to the crystallography data. Negatively
and positively charged surface areas are colored
red and blue, respectively. The N-terminal tip
important in LPS interaction is marked with an
orange circle, the newly described groove of LBP
is labeled (green box).
(B) The structure of the C-terminal groove is drawn
schematically. Thecentral andC-terminal domains
are colored in blue and green, respectively. The
bound phospholipid molecule is shown in red.
The molecular surface is represented by a mesh.
The C-terminal groove is 26 A˚ wide and 13 A˚ deep.
(C) Ribbon diagram of a model of human LBP
based on the murine crystallography data. Apart
from mutations found in the C-terminal groove
region (box), two mutations have been described
(red): a mutation C291T affecting amino acid 98
(rs2232582) and a synonymous mutation at posi-
tion 204 (A613G, rs2232596).
(D) Enlargement of a model of the groove region in
human LBP. Of note, the phenylalanine core here
consists of only four Phe residues (black). In order
to mark other mutations found in this region, the
molecule was turned with the A loop marked (red).
Several less frequent mutations described in the
NCBI database are also marked in red. Marked in
bold red are two mutations of interest: one is
F436L previously described by others to be of
clinical relevance (rs2232618, see text), and the
other is a newly identified mutation analyzed by us
in more detail affecting amino acid 333
(rs2232613). Note that the latter mutation is in
close proximity to the phenylalanine core region.
See also Figure S3.
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Crystallography and Mutational Analysis of LBPand therefore cannot generate strong hydrophobic interactions.
Due to the shift of the C-terminal domain of LBP, several interac-
tions at the interface between it and the central domain are
affected: In human BPI, Leu364 forms hydrophobic interactions
with Phe294, Phe366, Leu357, and Met397 (Figure 2C). How-
ever, in LBP, Ile348 corresponding to Leu364 is shifted by
approximately 12 A˚ and creates new hydrophobic interactions
with Leu358, Phe463, and Leu356 (Figure 2D). The position of
Leu356 is also shifted in LBP and participates in new hydro-
phobic interactions with Phe463, Leu391, Ala389, Leu358, and
Ile348.
The structural shift of the C-terminal domain of LBP is associ-
ated with 10 degree rotation of the B’ helix connecting the
C-terminal and central domains (Figure 2E). This movement
appears to be initiated by small structural changes in the loop
preceding the B’ helix. Conformation of this b15-B’ loop is stabi-650 Immunity 39, 647–660, October 17, 2013 ª2013 Elsevier Inc.lized by an unusual hydrophobic core
composed of six phenylalanines at posi-
tions 321, 324, 379, 419, 424, and 427
(Figure 2F). This phenylalanine core is
absent in BPI because Phe424 and 427
are changed into a leucine and aspartate,
respectively. The remaining four phenyl-alanines of BPI are farther apart as a result of structural changes
induced by multiple proline residues. Prolines have restricted
backbone conformations due to the cyclic nature of their side
chains. Pro426 and Pro428 in BPI pull Phe427, corresponding
to Phe419 of LBP, away from the putative phenylalanine core
by 2.8 A˚ (Figure 2G). These prolines are replaced by Met418
and Asn420 in LBP. Pro323 of LBP, replaced by Thr331 in BPI,
changes the conformation of the loop between the a1 and a2
helices. Because of this, the side chain of Phe324 can penetrate
4.7 A˚ into the protein core completing the phenylalanine core.
The Structure of the C-Terminal Groove Allows for
Modeling of Relevant Mutations found in Human LBP
Like BPI, LBP contains two phospholipid binding pockets (Fig-
ure 1A). The N-terminal pocket of LBP with its bound phospho-
lipid is similar to that of BPI. It is formed by the A and B helices,
Immunity
Crystallography and Mutational Analysis of LBPtogether with the b2- to b6-strands of the N-terminal domain and
hydrophobic residues from the b sheet of the central domain.
The head group of the phospholipid is exposed to solvent, and
the hydrophobic fatty acid chains are buried inside the pocket.
The opening of the N-terminal pocket is surrounded by
conserved positively charged amino acids interacting with the
negatively charged phosphate group of the phospholipid. The
phospholipid binding pocket in the C-terminal domain of LBP
is different in both shape and size from that of BPI; the pocket
of LBP is rotated by 30 degrees relative to the N-terminal
pocket (Figure 1B), and this domain movement changes the
orientation of the C-terminal pocket such that the two pockets
point in different directions. Residues from the A’ loop, B’ helix,
and b11–b16 strands form the hydrophobic wall interacting
with the fatty acid chain of the phospholipid (Figure 3B).
Because the head group does not interact effectively with pro-
teins, its conformation is flexible and only barely visible in one
of the monomers in the asymmetric crystal unit. The transition
of the A’ helix to the A’ loop rotates the N’ beta sheet of the C-ter-
minal domain, and the area occupied by the A’ helix and the N’
beta sheet in BPI turns into a wide groove in LBP. The phospho-
lipid binding pocket is located at the bottom of the groove and is
continuous with the groove. Unlike the area of the N-terminal
phospholipid pocket, the surface of the groove is covered
with the negatively charged residues Asp223, Glu250, Asp283,
Asp305, Asp306, and Asp311, Glu338, Asp439, Glu443, and
Asp468 (Figure 3A).
In order to investigate whether mutations described for human
LBP affect the structures found in LBP, a model of human LBP
was created with the crystallography information of murine
LBP because murine and human LBP share higher sequence
homology as human LBP and BPI (Figure 3C). This model was
of high quality as described in detail in the Supplemental Exper-
imental Procedures. A mutation affecting amino acid 98
(rs2232582, marked in Figure 3C) affects an exposed loop and
has been described to confer a risk for several infectious and in-
flammatory diseases (Hubacek et al., 2001). A synonymous SNP
at position 204 also is in close proximity and may be haplotype-
linked to functional relevant SNPs (Vollmer et al., 2009). Within
the groove region we focused on two mutations (Figure 3D,
bold red), one being in close proximity to the phenylalanine
core, located at the outer surface of the protein and thus poten-
tially accessible by proteinases (residue 333: proline changed to
leucine, bold red, Figure 3D, rs2232613). Furthermore, we found
a mutation to be located within the identified groove region (res-
idue 436: phenylalanine changed into leucine, rs2232618, bold
red, Figure 3D) (Hubacek et al., 2001). Other mutations at amino
acids 339, 364, or 445 (Figure 3D, marked red) are very rare, and
some are only found in African populations.
Discovery and Frequency of the LBP P333L Mutation
(rs2232613) and Potential Structural Consequences
We analyzed LBP serum concentrations by using a commercial
ELISA assay in a cohort of over 3,000 German children and
detected several individuals with apparently low serum concen-
trations of LBP. These children were homozygous for the
rs2232613 LBP SNP described above (Figure 3D), suggesting
that the commercial ELISA assay used was unable to detect
the LBP mutant resulting from this genetic variation. In a cross-sectional population study of 3,061 German children in Munich
(n = 1142) and Dresden (n = 1919) (Schedel et al., 2008), the
allelic frequency of this SNP was found to be 0.08 (Table S1).
In a cohort of healthy adults from Berlin, we observed a similar
frequency. Whereas 0.46% homozygous children were de-
tected, no homozygous individuals were found among the 627
healthy adults tested.
Utilizing the homology model, we found aa333, which is highly
conserved, to be exposed at the C-terminal tip of the LBP mole-
cule and part of a small helix (Figure 3D). An exchange from pro-
line to leucine leads to the generation of a potential cleavage site
for the proteases Chymotrypsin, Pepsin und ProteinaseK (Fig-
ures 4A and B). The calculated size of the resulting fragments
is 33.9 (for aa1–333), and 15.8 kDa (for aa334–452) adding up
to the size of nonglycosylated wild-type (WT) LBP of 49.7 kDa
(Figure 4C). After cleavage at position 333, disintegration of the
two potential LBP fragments would lead to a disruption of both
phospholipids binding pockets (Figure 4D). This may cause
additional structural rearrangements driven by the unfavorable
exposure of hydrophobic regions, which dissociation of the
two fragments would entail. Even in a nondissociated state,
cleavage of the peptide bond at P333 is predicted to result in
substantial structural changes as assessed by 10 ns molecular
dynamics simulation of human LBP P333L and WT models (Fig-
ure S4; Supplemental Experimental Procedures). The outer tip of
the LBPmolecule formed by amino acids 319, 322, 327, and 330
at the C terminus would change its conformation and surface
charges in the ‘‘cleaved’’ P333L model of human LBP, whereas
in WT-LBP side-chain orientation and surface charge remain
more stable over the course of the simulation (Figure S4). Thus
it is suggested that peptide cleavage results in conformational
distortions likely to impact the ability of LBP to bind LPS and/
or LP, and might also affect its serum half-life.
Sera from P333L Carriers Contain Cleaved LBP
Next we analyzed sera from individuals genotyped for LBP by
Immunoblot (Figure 4E, left two panels). Sera from P333L car-
riers were obtained from two individuals carrying the mutation
in a homozygous form (7 and 8) and four individuals carrying
the heterozygous form (3–6), and were compared to individuals
with the ‘‘normal’’ LBP genotype (1 and 2). A polyclonal anti-
LBP antiserum revealed the typical double band at 58 and
60 kDa known to be caused by two different glycosylation forms
of LBP, as expected for theWT individuals (Figure 4E, left panel).
A similar, weaker signal was also detected in the serum of the
heterozygous SNP carriers. In sera from homozygous individ-
uals, almost no bands at 58 and 60 kDa were visible. A second
polyclonal antiserum detected an additional band at 23 kDa in
sera from individuals homozygous for the rs2232613 SNP (Fig-
ure 4E, second panel from left). This size corresponds to the
smaller postulated cleavage product (15.8 kDa plus four N-Gly-
cans). The expected larger fragment at 37 kDawas not detected,
which might be caused by a lack of reactivity of this fragment
with the antisera used, or by subsequent degradation in serum.
Cloning and Expression of the LBP Mutant Reveals
Severe Functional Consequences
Next, WT and the c998t mutated LBP prolonged by six histidines
(His-Tag) were expressed in HEK293 cells and detected byImmunity 39, 647–660, October 17, 2013 ª2013 Elsevier Inc. 651
Figure 4. Homology Modeling and Immunoblot of Mutated Human LBP (rs2232613 SNP) Reveals Potential Cleavage of LBP
(A) Cartoon diagram of human LBP colored as in Figure 1 with putative N-Glycans shown in orange, and the mutated amino acid at position 333 marked in red.
(B) Enlargement of the C terminus.
(C) Putative LBP-fragments (black, white) following cleavage at position 333. Surface representation of LBP homology model.
(D) Dissociated fragments colored according to predicted surface hydrophobicity (green, hydrophobic; blue, hydrophilic). The two lipid binding cavities of LBP are
potentially compromised by cleavage at P/L333. Putative N-Glycans are shown in orange. Human LBP is predicted to also contain two hydrophobic pockets that
are linked to form a hydrophobic channel inside the molecule. Evidently, the hydrophobic cavities would be compromised after cleavage. Fragment 1 (1–332)
would retain one N-glycan, and fragment 2 (333–481) would retain four N-glycans.
(legend continued on next page)
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Crystallography and Mutational Analysis of LBPELISA analysis, and protein size was analyzed by Immunoblot
(Figure 4E). For details, see Supplemental Experimental Proce-
dures and Figure S5. For WT-LBP, a monoclonal antibody de-
tected one band at the expected size of approximately 55 kDa.
The recombinant protein did not display a double band and
was slightly smaller most likely as a result of different glycosyla-
tion as compared to serum-LBP. No band of this size and no
other positive signals were detected for the mutant LBP
(P333L) (Figure 4E, right panel). The polyclonal antiserum that
detected the small LBP fragment in serum identified two addi-
tional bands for the mutant recombinant protein. The first was
of similar size as seen in sera from homozygous patients at
23 kDa and the second at 37 kDa matched the hypothetical
size of the larger LBP fragment (33.9 kDa plus one N-Glycan),
which would be obtained by protease cleavage (Figure 4E, sec-
ond panel from the right). Another polyclonal antiserum detected
a band at approximately 55 kDa during purification of the mutant
recombinant protein (Figure S5). This suggests that the mutated
protein is initially expressed in full size and then may be cleaved
or degraded. Purification in the presence of proteinase inhibitors
did not change the results (data not shown).
P333L LBP Does Not Bind LPS or Induce Cytokines
In Vitro
In order to analyze functional differences of LBP from donors
differing in their rs2232613 genotype, blood was drawn and
serum separated from healthy volunteers genotyped for the
LBP mutation. We immobilized LPS and LPs on microtiter plates
and inoculated themwith the different sera. Binding of LBP to the
bacterial ligands was assessed by an ELISA-type assay as
described (Lamping et al., 1996). While sera from individuals
WT for the rs2232613 SNP (+/+) bound to both forms of LPS,
sera from homozygous mutated individuals (/) completely
lacked LPS-binding capacity (Figure 5A, upper panels). Sera
from heterozygous individuals (+/) displayed approximately
50% activity. Similar results, although less pronounced, were
obtained for lipopeptides, which also are ligands of LBP (Fig-
ure 5A, lower panels): Confirming previous results (Schro¨der
et al., 2004), we observed a biphasic dose-response curve for
LBP toward LPS recognition, with high concentrations of LBP-
containing serum inhibiting binding of LPS, but not of lipopepti-
des (Figure 5A). Cell supernatants containing mutant and
WT-LBP were also tested for their ability to bind to bacterial
ligands and we observed a profound difference in the binding
capacity between these proteins (Figure 5B). Binding of WT-
LBP to two types of LPS and LP tested was observed at concen-
trations of 10–100 ng/ml. In contrast, mutant LBP was unable to
bind lipopeptides when these concentrations were applied. LPS
binding was impaired, however, some interaction was observed
at higher concentrations.
Next, the murine macrophage cell line RAW264.7 was stimu-
lated with bacterial ligands in the presence and absence of(E) Human sera from volunteers genotyped for the LBPSNP rs2232613 (left two pa
(P333L) (right two panels) were resolved by SDS-Page under reducing conditions a
antibodies (left panel, ‘‘polyclonal I’’ obtained from Abcam; middle panels, ‘‘polyc
from Biometec, for details see Experimental Procedures section). +/+, homozy
numbers on each lane represent sera from individual volunteers. A size marker ha
left two panels. See also Figure S4.sera from individuals differing in their LBP genotype (Figure 6A),
as well as in the presence of the recombinant LBP variants (Fig-
ure 6B). We observed a clear difference for LPS- and diacylated
LP-induced cytokine secretion in the presence of 5% serum.
Sera from individuals heterozygous for the LBP mutation
enhanced mTNF-induction by approximately 50% as compared
to sera from WT-LBP individuals. With triacylated LP and 5%
sera, however, no difference was visible. With 1% sera, there
was a discrete difference as seen for diacylated LP and LPS
but less pronounced. mTNF-induction induced by bacterial
ligands was enhanced by 100 ng/ml recombinant WT-LBP,
whereas cell stimulation in the presence of mutant LBP was
50% or less. Similar results were obtained with only 10 ng/ml
of recombinant LBP (data not shown). Identical results were
also obtained with the human THP-1 cell line andwith freshly iso-
lated human monocytes measuring hIL8- and hTNF-release,
respectively (data not shown).
Individuals with the LBP SNP Have Lower Cytokine
Concentrations in Serum after Experimental
LPS-Application
To ask whether the LBP genotype influences cytokine release
induced by LPS in humans in vivo, we analyzed cytokine induc-
tion following injection of LPS. A group of 54 healthy volunteers
of Caucasian origin were infused with purified LPS prepared
from E. coli (O:113, 2 ng/kg) in vivo. Cytokines (TNF and
IL-1b) were measured in serum at different time points. All
subjects were genotyped for the rs2232613 LBP SNP as
described, and 45 were WT and 9 heterozygous corresponding
to an allelic frequency of 0.16, which is higher but roughly as
expected in Europe. Mean cytokine levels were compared by
unpaired t test, to assess the strength of association between
the rs2232613 (LBPP333L+/) genotype and the inflammatory
response. Individuals heterozygous for the LBP mutation
showed a slightly diminished response (Figure S6): For TNF
release, this difference at 1 hr after LPS injection was significant
(Figure S6A, p = 0.013). The IL-1b release was slightly delayed
and diminished without reaching statistical significance (Fig-
ure S6B). For a clear difference, most likely larger groups of
individuals have to be included in order to also include homozy-
gous individuals.
LBP SNP Carriers Produce Fewer Cytokines during
Pneumonia and Have a More Severe Course of Infection
Serum cytokine concentrations were also assessed in a group of
patients originating from Athens, Greece, suffering from venti-
lator-associated pneumonia caused by Gram-negative bacteria
(for details, see Supplemental Experimental Procedures, ‘‘VAP
patients’’). These individuals were genotyped for the LBP SNP,
and of 157 patients, 10 were found to be heterozygous and 2
homozygous for the LBP variant leading to an allelic frequency
of 0.07. In vivo TNF-measurement showed that LBPSNP carriersnels) and cell culture supernatant containing recombinantWT andmutated LBP
nd transferred to PVDFmembranes followed by probing with different anti-LBP
lonal II’’ obtained from Xoma; right panel, monoclonal antibody biG42 obtained
gous WT; +/, heterozygous; and /, mutated (LBP SNP rs2232613). The
s been run on all three gels on the right, and the sizes are indicated between the
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Figure 5. The Ability of Human Serum to
Bind Bacterial Ligands Depends on the
LBP Genotype and Resulting Protein
Variants
Binding of human sera (A) or cell culture super-
natant containing recombinant LBP (B) to bacterial
ligands was assessed in an ELISA-like assay
following coating of the potential ligands (‘‘rough’’,
rLPS from S. Minnesota; ‘‘smooth’’, sLPS from
E. coli 0111:B4; diacylated lipopeptide, LP2; tri-
acylated lipopeptide, LP3) to microtiter plates and
incubation with human sera or cell culture super-
natant and detection with an anti-LBP monoclonal
antibody. Serum and cell culture supernatants
were applied in increasing concentrations, and
supernatants were assessed for LBP concentra-
tions by ELISA. Each point represents the mean of
two wells ± SEM, and one representative of three
separate experiments with similar results. Statis-
tics were calculated with the two-sided paired
t test. *p < 0.05, **p < 0.01.
(A) Human volunteers were genotyped regarding
the presence of the rs2232613 SNP, and blood
was drawn and serum prepared. LBP+/+,
WT; LBP+/, heterozygous; LBP/, mutated
(rs2232613 SNP).
(B) Cell culture supernatant containing recombi-
nant WT and mutated LBP (LBP WT, LBP mut).
See also Figure S5.
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1.76 pg/ml) as compared to WT individuals (18.4 ± 4.9 pg/ml,
p = 0.014). The two homozygous individuals had the lowest
TNF concentrations (3.93 ± 1.76 pg/ml) further supporting our
in vitro results of LBP being a nonredundant modulator of the
systemic in vivo inflammatory response. In another clinical trial
with patients going through an acute-phase response, heterozy-
gous LBP SNP carriers exhibited lower cytokine concentrations,
and homozygous individuals almost lacked the typical acute-
phase cytokine induction (data not shown).
To assess the relevance of the LBP rs2232613 SNP for the
clinical course of infection, we analyzed a group of 424 patients
with a prolonged intensive care unit stay at the Charite´, Berlin,
Germany (for inclusion criteria, see the Supplemental Experi-
mental Procedures and Kumpf et al., 2010). Individuals carrying
the rs2232613 SNP were compared to WT individuals for the
rate and course of infectious complications (Table 1). Sixty-
one SNP carriers were identified, with 57 being heterozygous654 Immunity 39, 647–660, October 17, 2013 ª2013 Elsevier Inc.and 4 homozygous, leading to an allelic
frequency of 0.08, similar to the control
groups reported here. Comparison of
the SNP carrier and the WT group re-
vealed similar disease severity scores
on admission, as well as frequencies of
infectious complications (Table S2). Of
note, the four individuals homozygous
for the LBP SNP investigated all devel-
oped infectious complications, and three
out of four became septic. Due to the
low number, however, no statistical tests
could be performed. For the heterozy-gous individuals, no change in susceptibility for infectious
diseases could be detected.
When comparing the course of infectious complications, LBP
rs2232613 SNP carriers and homozygous and heterozygous in-
dividuals combined exhibited a more severe course of disease,
leading to higher mortality rates following sepsis and pneu-
monia (Table 1): The overall trend toward higher mortality in
SNP carriers versus WT individuals (7/61 [11.5%] versus 21/
363 [5.8%]) increased in the patient subgroup with septic com-
plications (7/33 [21.2%] versus 18/202 [8.9%]). In patients with
sepsis caused by Gram-negative bacteria, this difference was
almost significant (5/19 [26.3%] versus 11/117 [9.4%], p =
0.05). A statistically significant difference in outcome was
observed for hospital-acquired pneumonia (HAP) (5/15 [33%]
in the LBP SNP group versus 7/85 [8.2%] in the WT cohort,
OR 5.6, CI 1.48–20.92, p = 0.02), and also for HAP caused
by Gram-negative bacteria (4/11 [36.4%] versus 4/49 [8.0%]
in the wt group, OR 6.6, CI 1.33–32.48, p = 0.03). Comparison
Figure 6. LBP Genotype Determines the
Ability of Human Sera to Modulate LPS- or
Lipopeptide-Induced TNF Release from a
Macrophage Cell Line
The murine macrophage cell line RAW 264.7 was
incubated with various bacterial ligands (sLPS,
LP2, and LP3) in the absence or presence of sera
from individuals genotyped for the rs2232613
mutation (A) and in the absence or presence of WT
and mutated recombinant LBP (B). Secretion of
TNF into the supernatant was assessed after 4 hr
by ELISA. (A) Human sera obtained from volun-
teers differing in the LBP genotype was used as
source of LBP. Due to limited availability, sera
from homozygous individuals were not used in
this assay. LBP+/+, Serum obtained from WT
individuals; LBP+/, serum from heterozygous
individuals (rs2232613 SNP). (B) We added
100 ng/ml purified recombinant LBP; LBP-WT,
WT-LBP; LBPc998t, mutated LBP. Each bar
represents the mean of two wells ± SEM, and one
representative of three separate experiments with
similar results is shown. Statistics were calculated
with the two-sided paired t test. *p < 0.05, **p <
0.01. See also Figure S6.
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ences in the incidence of comorbidities: The strongest influ-
ence was recorded with renal and hepatic disease, but these
were rare and equally distributed over the study cohorts. Un-
evenly distributed comorbidities had no influence on mortality.
This is shown in detail in the Supplemental Information (Table
S2). Analyzing the course of disease over time, as early as
20 days after onset of the infectious complications, mortality
rates were higher among SNP carriers, as shown for patients
with pneumonia and pneumonia caused by Gram-negative
bacteria (Figure S7). The multivariate analysis in this study
does not conclusively reveal why patients in the SNP carrier
group had a less favorable outcome. In another trial, 197 pa-
tients with community-acquired pneumonia (CAP) caused by
S. pneumoniae were analyzed, and individuals heterozygous
for the LBP rs2232613 SNP displayed similar mortality rates
as compared to WT individuals (9 versus 8%; data not shown).
Although a less pronounced effect for LBP toward recognition
of S. pneumoniae as compared to Gram-negative bacteria is
reasonable, study numbers are still too low to draw definitive
conclusions.Immunity 39, 647–660,DISCUSSION
In this report, we present the first crystal
structure of LBP and report on a frequent
genetic variation altering its structure
leading to a dysfunctional LBP. We
furthermore present evidence that this
variation leads to an altered cytokine
response and that carriers of this muta-
tion have an increased risk for a more se-
vere course of clinical infections. These
results show that structural integrity of
LBP is crucial for the host for successfulcytokine induction following bacterial stimulation and potentially
for fighting infectious diseases.
Solving of the LBP structure reveals that the C-terminal hydro-
phobic pocket differs structurally from that found in BPI and from
models suggested for LBP. The transition of the A’ helix to the A’
loop in LBP disrupts interactions at the interface between the
C-terminal and the central domain, and the closed, barrel-like
structure is partially open to the solvent area. This change gener-
ates a negatively charged groove at the interface between the
central and C-terminal domains in LBP, the function of which is
currently unknown. This unexpected domain, and the fact that
the mutation described here affects this region, might provide
new clues to the different properties of BPI and LBP. Both pro-
teins can bind LPS with nanomolar affinity, but only LBP can
transfer LPS to membrane-bound or soluble CD14 (Beamer
et al., 1998) and subsequently to the MD-2-TLR4 complex.
Because the formation of the groove is the most dramatic struc-
tural change in theC-terminal domain, and groove-like structures
are frequently foundat protein interactionsites, itmightbe thesite
of interactionwithCD14andmediateLPS transfer toMD-2-TLR4.
Mutagenesis experiments should allow this idea to be tested.October 17, 2013 ª2013 Elsevier Inc. 655
Table 1. Distribution of Mortality in Patients in Relation to the LBP C988T Polymorphism
Characteristic (Number of patients)
Wild-Type - CC SNP - CT/TT
ORc CIc p valuecDeath Survival Death Survival
All patients (n = 424) 21 (5.8%) 342 (94.2%) 7 (11.5%) 54 (88.5%) 2.1 0.86–5.20 0.10
Septic complicationsa (n = 235) 18 (8.9%) 184 (91.1%) 7 (21.2%) 26 (78.8%) 2.8 1.05–7.22 0.06
Septic complications, Gram-negativeb (n = 136) 11 (9.4%) 106 (90.6%) 5 (26.3%) 14 (73.7%) 3.4 1.04–11.37 0.05
Pneumonia (n=100) 7 (8.2%) 79 (91.8%) 5 (33.3%) 10 (66.7%) 5.6 1.48–20.92 0.02
Pneumonia, Gram-negativeb (n=61) 4 (8.0%) 46 (92.0%) 4 (36.4%) 7 (63.6%) 6.6 1.33–32.48 0.03
In a retrospective analysis, 424 patients that underwent major surgery with a prolonged ICU stay (for details see Experimental Procedures and Sup-
plemental Information) were analyzed for clinical outcome. DNAwas analyzed for presence of the rs2232613 LBPSNP, and clinical datawere related to
the genotype. There was a trend toward highermortality in individuals heterozygous or homozygous for the rs2232613 SNP (11% versus 6%mortality).
A significant correlation was seen among patients either suffering from sepsis or pneumonia caused by Gram-negative bacteria. Among these groups,
more individuals mutated for LBP died as compared to WT individuals. See also Figure S7 and Tables S2 and S3.
aSepsis, severe sepsis, and septic shock; for definition, see: Supplemental Experimental Procedures.
bInfection caused by Gram-negative organism (microbiologically proven).
cCalculated with Fisher’s exact test.
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that a frequent genetic variation causes the protein to be
dysfunctional, altering its induction of a cytokine response
in vivo. Although the clinical data have to be confirmed by larger
trials, we present evidence that heterozygosity for this mutation
is a risk factor for a more severe course of clinical infections. In
addition, more complex genotyping strategies might be advis-
able, including genome-wide association studies (GWASs).
Our results suggest the lung as an organ affected by mutation
carriers, and this is supported by a recent GWAS analysis per-
formed in Korea, in which copy-number variations (CNV) of
genes were related to clinical pulmonary function data of
patients. The authors found five gene clusters correlating with
pulmonary function, and among these, the genes of the LBP/
BPI/Plunc superfamily obtained the highest score (Lee et al.,
2011). Although it is not clear whether other proteins of this
cluster are functionally relevant too, this technique potentially
supports our finding that variations of LBP are crucial for lung
function in vivo.
Our results suggest that the LBP mutation results in a dimin-
ished inflammatory response after bacterial challenge. One
explanation for a less favorable outcome during disease is that
the amino acid exchange at position 333 of LBP leads to a
reduced ability to recognize pathogenic bacteria via LPS or lipo-
peptides. This might lead to a reduced cytokine response of the
host resulting in a weakened defense during infections. In line
with this, the phenotype of individuals carrying the rs2232613
SNP resembles our own early observations from the Lbp
knockout (k.o.) mouse (Wurfel et al., 1997): Whole blood from
mice lacking LBP was less responsive to LPS in regards to
TNF release, and exogenous recombinant LBP was able to
restore this reactivity. The differences in the in vivo responses
to LPS injection, however, were less pronounced, correlating
with the data presented here with human volunteers receiving
LPS intravenously: During experimental endotoxemia, individ-
uals carrying the LBP mutation exhibited only a slightly reduced
cytokine response when compared to the LBP WT individuals.
The Lbp k.o. mouse is severely diminished in cytokine
response to LPS (and thus ‘‘protected’’ from its lethal effects),
but exhibits increased lethality upon bacterial stimulation656 Immunity 39, 647–660, October 17, 2013 ª2013 Elsevier Inc.(Branger et al., 2004; Jack et al., 1997). The mutation described
here might lead to a similar mechanism because our results also
point to an increased lethality during infections combined with a
diminished cytokine response. Further supporting this interpre-
tation, in Lbp k.o. mice bacterial overgrowth was found in infec-
tion models, paralleled by a lack of innate immune responses
(Yang et al., 2002). In mice, this phenotype could be reverted
by a ‘‘gene-therapy’’ approach aimed at overexpressing LBP in
the lungs (Hemmila et al., 2006). Our clinical data have to be
confirmed by larger trials before a treatment with LBP should
be considered for improving outcome during clinical infections.
In certain experimental models, an ‘‘overwhelming’’ cytokine
induction by LPS also contributes to lethality, and anti-LBP-an-
tibodies aimed at blocking the LBP-mediated cytokine release
were beneficial (Le Roy et al., 1999). One clinical study found
that genetic variations within the LBP promoter leading to higher
LBP concentrations correlated with susceptibility to Gram-nega-
tive infections and worse outcome (Chien et al., 2008). These
findings underscore the importance of LBP and its genetic vari-
ations and might reflect on the known biphasic dose-response
curve of LBP with both, absence, and high concentrations of
LBP leading to a reduced immune response (Lamping et al.,
1998). It has been proposed that during severe clinical infections,
both, a proinflammatory, and an anti-inflammatory phase exist,
and that a prolonged anti-inflammatory phase may be detri-
mental (Kumpf et al., 2010; Muenzer et al., 2010). LBP can also
inhibit the inflammatory response; for example, high concentra-
tions of LBP in the presence of serum lipoproteins can block
LPS-responses and protect mice in disease models (Hamann
et al., 2005; Lamping et al., 1998; Vreugdenhil et al., 2003;
Zweigner et al., 2001). This LBP function of LPS-detoxification
might be also impaired in SNP carriers; however, our experi-
mental systems were not sufficient to investigate this. LPS-
detoxification and subsequent inhibition of inflammation is
particularly important for pulmonary LBP because it has been
shown to protect from the effects caused by Gram-negative
or -positive bacteria, or both (Knapp et al., 2006; Mueller
et al., 2006).
In a recent clinical trial, genetic variations in the promoter
region of the LBP gene have been linked to sepsis incidence
Table 2. Oligonucleotides Used for Genotyping LBP c998t
SNP ID Primers (50- > 30) Probes (50- > 30)
LBP rs2232613 LBP F: CAACTTCCAGCTTTATCTGACTC sensor Red640-GGCTCTACCCCAACATGAA—PH
Primer R: CACAAAGGCATCTATCTCCATATA anchor CCCAGTTAGCC—FL (LNA: bold letters indicate locked
nucleotides)
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number of SNPs and identified a haplotype block linked to sepsis
susceptibility; however, they did not include the rs2232613 LBP
SNP in their analysis. Furthermore, the patients’ inclusion criteria
differed from ours, so it could not serve as confirmatory group for
our study. Only a subgroup of this cohort were postsurgical
patients comparable to the cohort of this study, and within this
small group a linkage of the rs2232613 LBP SNP (occurring
less frequently in Spain; allelic frequency: 0.05) with pulmonary
infection caused by Gram-negative bacteria was found when
we reanalyzed the Spanish samples (data not shown). However,
the small patient number did not allow for the statistical analysis.
Recent studies have linked LBP variations present in Asia with in-
flammatory diseases: Takeuchi et al. found that within a region
claimed to contain susceptibility genes for type 2 diabetes, it is
LBP and its variations that contributes to disease risk (Takeuchi
et al., 2007). Other inflammatory diseases such as atheroscle-
rosis and metabolic syndrome have also recently have been
linked to LBP: LBP concentrations correlate with metabolic syn-
drome, and a genetic variation in aa436 (rs2232618) showed a
weak correlation with LBP concentrations (Gonzalez-Quintela
et al., 2013). An increased risk for myocardial infarction was
seen earlier when mutations in LBP at either amino acid 98 or
436 are present (Hubacek et al., 2002). The same mutations
recently were found to correlate with the degree of atheroscle-
rosis in a cerebral infarction cohort asmeasured by intima-media
thickness (IMT) (Zhan et al., 2012). Of note, the LBP rs2232618
mutation affecting aa436 found to correlate with metabolic syn-
drome and atherosclerosis, by the structural data presented
here was confirmed to be located at a central position close to
the newly identified ‘‘groove’’ region.
In conclusion, we found a large structural difference between
the C-terminal domains of LBP and BPI. This difference appears
to be due to only a few amino acid changes in the linker regions
between the central and C-terminal domains. The structural shift
of the C-terminal domain in LBP generates a negatively charged
groove in the interface between the central and C-terminal do-
mains that might play an important role in the LPS transfer reac-
tion. We identified a frequent LBP mutation affecting this region,
leading to an altered function of this protein with potential clinical
consequences particularly during sepsis and pneumonia. The
exact role of this mutation in vivo currently cannot be completely
elucidated because LBP might also play a role in inflammatory
diseases affecting overall clinical outcome. The mutant LBP
described here has impaired ligand-binding and cytokine-induc-
tion function, and the presence of this genetic variation is asso-
ciated with lower amounts of cytokine induction in vitro, and also
in vivo, during experimental endotoxemia and infection. Our
retrospective clinical analysis proposes that individuals carrying
this mutation are at risk for fatal sepsis and pneumonia, although
these results have to be confirmed in larger trials. These findings
might have consequences for individual patient’s risk assess-ment, and support the concept of LBP as key mediator of the in-
flammatory response. The results might furthermore improve our
understanding of the complex LPS-recognition machinery and
could potentially help in the development of novel immunomod-
ulatory therapies.
EXPERIMENTAL PROCEDURES
Expression and Purification of Recombinant Murine LBP for
Crystallization
The cloned plasmid containing the murine LBP sequence was cotransfected
with Baculogold (BD Biosciences) into SF9 insect cells as described in the
manufacturer’s protocol. To produce the protein, we cultured Hi Five insect
cells in SF900II serum-free medium (both: GIBCO/Invitrogen) and incubated
them for 3 days with the recombinant virus. The secreted LBP with the Histi-
dine tag was purified by SP-Sepharose Fast Flow ion-exchange chromatog-
raphy (GE Healthcare Life Sciences). The fractions containing LBP identified
by SDS-PAGE were then loaded onto a Ni-NTA (Peptron) affinity column and
eluted with 0.5 M imidazole, pH 7.0. The fusion protein was purified by
Superdex-200 gel filtration chromatography (GE Healthcare Life Sciences).
LBP-containing fractions were pooled and concentrated to 10 mg/ml for
crystallization.
Crystallization, Data Collection, Structure Determination, and
Refinement
Crystals were grown by hanging drop vapor diffusion with 25%PEG 8,000 and
100mMMOPS (pH 6.5) at 22C. Diffraction data were collected at the BL41XU
beam line of SPring-8 and the 4A beamline of the Pohang Accelerator Labora-
tory with crystals flash-frozen at 170C in the crystallization buffer supple-
mented with 30% glycerol. Diffraction data were processed with the
HKL2000 package (Table S4) (Otwinowski and Minor, 1997). Initial phases
were obtained by molecular replacement technique with the reported BPI
structure as a search model (Beamer et al., 1997). Molecular replacement
calculation with the complete structural model of BPI did not give an accept-
able solution probably as a result of the extensive structural shift of the C-ter-
minal domain. Therefore, the probe structure was divided into N-terminal,
central, and C-terminal domains, and a reasonable solution was obtained
with the program PHASER (McCoy et al., 2005). The initial electron density
map was calculated to 2.9 A˚, and repeated cycles of refinement and model
building with CNS and O were performed (Bru¨nger et al., 1998; Jones et al.,
1991). The final model contained two protein molecules in the asymmetric
unit. We found three glycosylation sites in each protein monomer in the C-ter-
minal domain and assessed the quality of the final model with the program
PROCHECK (Laskowski et al., 1993).
SNP Genotyping
The LBP rs2232613 SNP (c998t) was determined by real-time PCR assayswith
subsequent melting curve analysis with a LightCycler 1.5 (Roche Diagnostics).
The PCR reaction was as follows: One reaction volume of 20 ml contained 2 ml
103 PCR Buffer, 2 mM MgCl2, 125 mM NTPs, 5 U Taq polymerase, 3 mg BSA,
primers at 0.5 mM (LBP F/R), fluorescence probes at 0.2 mMeach, and 5–20 ng
DNA. On the LightCycler 1.5 platform, parameters were as follows: initial dena-
turation at 95C 4min, 40 cycles of denaturation (95C 0 s), annealing (56C 10
s), and extension (72C 8 s) with subsequent melting curve analysis: 1 cycle at
95C10 s, 40C 30 s, followed by an increase of temperature to 80C at a slope
of 0.1C/s. Oligonucleotides were manufactured by TIB MOLBIOL. PCR
reagents were from Rapidozym. Sequenced controls representing different
genotypes were included in each reaction. See Table 2 for oligonucleotides
use for genotyping LBP c998t.Immunity 39, 647–660, October 17, 2013 ª2013 Elsevier Inc. 657
Table 3. Antibodies that Were Applied
Primary antibody, dilution Secondary antibody, dilution
Polyclonal antiserum I (Abcam) from
rabbit, 1:1,000
anti-rabbit IgG, 1:10,000
Polyclonal antibody II (Xoma) from
rabbit, 1:2,000
anti-rabbit IgG, 1:20,000
Polyclonal antiserum (R&D) from
goat, 1:250
anti-goat IgG, 1:5,000
Monoclonal antibody biG42
(Biometech) from mouse, 1:2,000
anti-mouse IgG, 1:10,000
Antigens were detected with enhanced chemiluminescence (Super
Signal West Pico Chemiluminescent Substrate, Thermo Fisher Scientific).
For reprobing, blots were stripped with Restore Immunoblot Stripping
Buffer (Thermo Fisher Scientific) for 15 min at room temperature.
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Mutagenesis in a plasmid encoding for human LBP including a 6-fold His-tag
was performed with the QuikChange II Site-Directed Mutagenesis Kit
(QIAGEN, Hilden, Germany) following the manufacturer’s instructions. The
primers used for creating the LBP mutant were c998t (50-AGCCAGGCTC
TACCTCAA CATGAACCTGGAAC), antisense-c998t (50-TCCAGGTTCATG
TTGAGGTAGAGCCTGGCTAA). The plasmids for WT and mutated LBP
were control sequenced and transfected in human embryonic kidney 293
(HEK293) cells with FuGene6 transfection reagent (Roche). HEK293 cells
were maintained in Dulbecco’s modified Eagle medium (GIBCO/Invitrogen)
including sodium pyruvate and 10% fetal bovine serum, 100 U/ml penicillin,
0.1 mg/ml streptomycin, and 200 mM L-glutamine. Transfection was main-
tained by the addition of Hygromycin B (PAA). Cells were cultured at 37C
in 5% CO2, 95% air humidified incubators. Supernatants containing the
recombinant proteins were collected continuously and stored at 20C.
LBP Immunoblotting
Samples containing LBP were resolved by SDS-PAGE under reducing
conditions (12.5% resolving gel) and transferred onto PVDF (Immobilon-P,
Millipore). The membrane was blocked for 1 hr in 5% dried skim milk in Phos-
phate-buffered saline (PBS). LBPwas probed with different primary antibodies
(obtained from Abcam, Xoma, R&D Systems, and Biometec) for 1 hr in PBS
containing 5% dried skim milk. After extensive washing, the membrane was
incubated for 1 hr with the secondary horseradish peroxidase (HRP)-conju-
gated antibody (Santa Cruz Biotechnology). See Table 3 for antibodies.
Binding Assay for Bacterial Ligands
Microtiter plates were coated with triacylated or diacylated LPs (Pam3CysSK4
or Pam2CysSK4, respectively) (EMC microcollections) and LPS derived from
E. coli O111:B4 or S. minnesota Re595 (Sigma) at 30 mg/ml in 100 mM
Na2CO3 (pH 9.2) for 6 hr at room temperature. Blocking was performed with
150 mM NaCl and 50 mM HEPES (pH 7.4) supplemented with 10 mg/ml
BSA (Carl Roth GmbH) for 30 min at room temperature. Plates were then
incubated with rhLBP from cell supernatant or with human sera at increasing
concentrations in the same buffer supplemented with 1 mg/ml BSA at room
temperature for 2 hr. LBP was detected by the monoclonal antibody bIG48
(Biometech) (1 mg/ml) and streptavidin-coupled horse radish peroxidase.
Detection of the cytokines took place with a chromogene substrate solution
(TMB, Seramun). The photometric reaction was stopped with 1M H2SO4 and
measured at OD 450 nm in an ELISA-reader (TECAN).
Berlin Patient Characteristics
Patients were treated at the ICU of the Robert-Ro¨ssle-Klinik of the Charite´-Uni-
versity Medical Center, Berlin, Germany, between 1999 and 2004. Inclusion
criteria were a prolonged length of stay of >7 days or premature death
following surgery indicating a complicated course. Case histories were exam-
ined for development of infectious complications and associatedmedical con-
ditions. Prior to surgery, sampled blood or tissue specimens were examined
for the LBP SNP. The study was approved by the local Ethics committee,658 Immunity 39, 647–660, October 17, 2013 ª2013 Elsevier Inc.and DNA testing was permitted by a signed broad written consent including
DNA testing before surgery. All stepswere performed according to the Helsinki
declaration. Further information for this cohort and the Athens trial on VAP can
be obtained in the Supplemental Information and in a previously published
study (Kumpf et al., 2010).
Statistical Analysis
Mean cytokine levels were compared by the unpaired t test. For group com-
parison the c2 test or Fisher’s exact test were employed. Odds ratios (OR)
were calculated by cross tabulation and c2 test and are reported with a 95%
confidence interval (CI). Influence of comorbidities was tested with binary
logistic regression. For survival analysis, the Kaplan-Meier survival analysis
with log-rank statistics was used. A two-tailed p value < 0.05 was considered
statistically significant. Statistical analysis was carried out after anonymiza-
tion of the patient’s data. For statistical analysis, either the software pack-
ages SPSS Version 14.0 (SPSS) or Prism Version 4.0 or 5.0 (GraphPad) were
used.
ACCESSION NUMBERS
The accession code for coordinates and diffraction data for the LBP structure
in this paper is 4M4D.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, three tables, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.immuni.2013.09.005.
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